China Market Opportunities for International Pharmas

 China’s pharmaceutical market presents an immense opportunity for  pharmaceutical companies from home and abroad. With a vast population,  significant unmet clinical needs, and a rapidly improving regulatory and market  access environment, international pharmas have strategically expanded to China  to invest in this dynamic market. Over the past four decades, these companies  have made substantial investments, introduced hundreds of innovative medicines,  and played a pivotal role in advancing the Chinese pharmaceutical industry. 

This L.E.K. Special Report explores the strategic opportunities available in  China for international pharmas. It explores the changing landscape of the  pharmaceutical market, examining how MNCs (Multinational Corporations)  have adapted to the “new normal”, fueled innovation, and embraced digital  transformation. Additionally, the report sheds light on China’s increasing  contributions to global innovation, offering a compelling reason for international  pharmas to explore partnerships and collaborations in the country. 

The report, ‘China Market Opportunities for International Pharmas’ is written by  Justin Wang, Partner at L.E.K. Consulting, China. It is an extract from the book  ‘Life Sciences Unicorns: From a China Investment Perspective’ written by Mr. Da  Liu and published by The Commercial Press (Singapore) Limited in June 2023.









Comments

Popular posts from this blog

Sizing the “New Three” in the Chinese Economy

A brand's quide to Chinese gifting habits 2023